GPER1 and neoplasm: Consequently, dual-targeting strategies combining EGFR inhibitors (e.g., gefitinib or erlotinib) with GPER antagonists may offer a more effective approach for reducing tumor burden and overcoming tamoxifen resistance in ERα−positive BC.